The overall safety profile of currently available vaccines directed against infectious diseases

Robert M. Jacobson, Kim S. Zabel, Gregory A. Poland

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The vaccines currently used worldwide for the prevention of infectious diseases are quite safe in comparison to most pharmaceutical and biological agents. Vaccine components may contribute to inflammatory, allergic or anaphylactic reactions. Most adverse events are transient and well-tolerated. Transient severe adverse reactions occur at rates of one in one thousand vaccinations; permanent severe adverse reactions occur on the order of one in one million. The most common of the severe adverse reactions are syncope and allergic reactions. Providers can take steps to prevent or ameliorate these reactions by pursuing both prelicensure testing (albeit limited) and postlicensure testing and monitoring. Systems that enhance the detection of safety concerns include national passive and active surveillance as well as regional vaccine registries and provider-based patient education. Since vaccines are used in universal programmes, their safety is paramount to their continued acceptance. Healthcare managers, including administrators of hospitals, clinics, practice groups, health maintenance organisations (HMOs) and managed care plans, can and should support providers in minimising adverse events associated with vaccines by supporting postvaccination observation policies, postlicensure testing and surveillance, vaccine registries and patient education systems.

Original languageEnglish (US)
Pages (from-to)215-223
Number of pages9
JournalExpert Opinion on Drug Safety
Volume2
Issue number3
DOIs
StatePublished - May 1 2003

Fingerprint

Communicable Diseases
Vaccines
Safety
Patient Education
Group Practice Hospitals
Registries
Hypersensitivity
Hospital Administrators
Health Maintenance Organizations
Biological Factors
Syncope
Managed Care Programs
Anaphylaxis
Vaccination
Observation
Delivery of Health Care
Pharmaceutical Preparations

Keywords

  • contraindications
  • records
  • registries
  • safety
  • safety management
  • vaccination
  • vaccination/adverse effects
  • vaccines
  • vaccines/adverse effects

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

The overall safety profile of currently available vaccines directed against infectious diseases. / Jacobson, Robert M.; Zabel, Kim S.; Poland, Gregory A.

In: Expert Opinion on Drug Safety, Vol. 2, No. 3, 01.05.2003, p. 215-223.

Research output: Contribution to journalArticle

Jacobson, Robert M. ; Zabel, Kim S. ; Poland, Gregory A. / The overall safety profile of currently available vaccines directed against infectious diseases. In: Expert Opinion on Drug Safety. 2003 ; Vol. 2, No. 3. pp. 215-223.
@article{8f3e45e09cc04498b717b80239fd19ce,
title = "The overall safety profile of currently available vaccines directed against infectious diseases",
abstract = "The vaccines currently used worldwide for the prevention of infectious diseases are quite safe in comparison to most pharmaceutical and biological agents. Vaccine components may contribute to inflammatory, allergic or anaphylactic reactions. Most adverse events are transient and well-tolerated. Transient severe adverse reactions occur at rates of one in one thousand vaccinations; permanent severe adverse reactions occur on the order of one in one million. The most common of the severe adverse reactions are syncope and allergic reactions. Providers can take steps to prevent or ameliorate these reactions by pursuing both prelicensure testing (albeit limited) and postlicensure testing and monitoring. Systems that enhance the detection of safety concerns include national passive and active surveillance as well as regional vaccine registries and provider-based patient education. Since vaccines are used in universal programmes, their safety is paramount to their continued acceptance. Healthcare managers, including administrators of hospitals, clinics, practice groups, health maintenance organisations (HMOs) and managed care plans, can and should support providers in minimising adverse events associated with vaccines by supporting postvaccination observation policies, postlicensure testing and surveillance, vaccine registries and patient education systems.",
keywords = "contraindications, records, registries, safety, safety management, vaccination, vaccination/adverse effects, vaccines, vaccines/adverse effects",
author = "Jacobson, {Robert M.} and Zabel, {Kim S.} and Poland, {Gregory A.}",
year = "2003",
month = "5",
day = "1",
doi = "10.1517/14740338.2.3.215",
language = "English (US)",
volume = "2",
pages = "215--223",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - The overall safety profile of currently available vaccines directed against infectious diseases

AU - Jacobson, Robert M.

AU - Zabel, Kim S.

AU - Poland, Gregory A.

PY - 2003/5/1

Y1 - 2003/5/1

N2 - The vaccines currently used worldwide for the prevention of infectious diseases are quite safe in comparison to most pharmaceutical and biological agents. Vaccine components may contribute to inflammatory, allergic or anaphylactic reactions. Most adverse events are transient and well-tolerated. Transient severe adverse reactions occur at rates of one in one thousand vaccinations; permanent severe adverse reactions occur on the order of one in one million. The most common of the severe adverse reactions are syncope and allergic reactions. Providers can take steps to prevent or ameliorate these reactions by pursuing both prelicensure testing (albeit limited) and postlicensure testing and monitoring. Systems that enhance the detection of safety concerns include national passive and active surveillance as well as regional vaccine registries and provider-based patient education. Since vaccines are used in universal programmes, their safety is paramount to their continued acceptance. Healthcare managers, including administrators of hospitals, clinics, practice groups, health maintenance organisations (HMOs) and managed care plans, can and should support providers in minimising adverse events associated with vaccines by supporting postvaccination observation policies, postlicensure testing and surveillance, vaccine registries and patient education systems.

AB - The vaccines currently used worldwide for the prevention of infectious diseases are quite safe in comparison to most pharmaceutical and biological agents. Vaccine components may contribute to inflammatory, allergic or anaphylactic reactions. Most adverse events are transient and well-tolerated. Transient severe adverse reactions occur at rates of one in one thousand vaccinations; permanent severe adverse reactions occur on the order of one in one million. The most common of the severe adverse reactions are syncope and allergic reactions. Providers can take steps to prevent or ameliorate these reactions by pursuing both prelicensure testing (albeit limited) and postlicensure testing and monitoring. Systems that enhance the detection of safety concerns include national passive and active surveillance as well as regional vaccine registries and provider-based patient education. Since vaccines are used in universal programmes, their safety is paramount to their continued acceptance. Healthcare managers, including administrators of hospitals, clinics, practice groups, health maintenance organisations (HMOs) and managed care plans, can and should support providers in minimising adverse events associated with vaccines by supporting postvaccination observation policies, postlicensure testing and surveillance, vaccine registries and patient education systems.

KW - contraindications

KW - records

KW - registries

KW - safety

KW - safety management

KW - vaccination

KW - vaccination/adverse effects

KW - vaccines

KW - vaccines/adverse effects

UR - http://www.scopus.com/inward/record.url?scp=0141818269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141818269&partnerID=8YFLogxK

U2 - 10.1517/14740338.2.3.215

DO - 10.1517/14740338.2.3.215

M3 - Article

VL - 2

SP - 215

EP - 223

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 3

ER -